Skip to main content

Chemical and Physical Biology Program

The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core.

AUTHORS

Bertron JL , Cho HP , Garcia-Barrantes PM , Panarese JD , Salovich JM , Nance KD , Engers DW , Rook JM , Blobaum AL , Niswender CM , Stauffer SR , Conn PJ , Lindsley CW , . Bioorganic & medicinal chemistry letters. 2018 7 1; 28(12). 2175-2179

ABSTRACT

This letter describes the chemical optimization of a new series of M positive allosteric modulators (PAMs) based on a novel benzomorpholine core, developed via iterative parallel synthesis, and culminating in the highly utilized rodent in vivo tool compound, VU0486846 (7), devoid of adverse effect liability. This is the first report of the optimization campaign (SAR and DMPK profiling) that led to the discovery of VU0486846 and details all of the challenges faced in allosteric modulator programs (both steep and flat SAR, as well as subtle structural changes affecting CNS penetration and overall physiochemical and DMPK properties).

This letter describes the chemical optimization of a new series of M positive allosteric modulators (PAMs) based on a novel benzomorpholine core, developed via iterative parallel synthesis, and culminating in the highly utilized rodent in vivo tool compound, VU0486846 (7), devoid of adverse effect liability. This is the first report of the optimization campaign (SAR and DMPK profiling) that led to the discovery of VU0486846 and details all of the challenges faced in allosteric modulator programs (both steep and flat SAR, as well as subtle structural changes affecting CNS penetration and overall physiochemical and DMPK properties).